These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12789688)

  • 1. Recent advances in de novo design strategy for practical lead identification.
    Honma T
    Med Res Rev; 2003 Sep; 23(5):606-32. PubMed ID: 12789688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in de novo design and scaffold hopping.
    Mauser H; Guba W
    Curr Opin Drug Discov Devel; 2008 May; 11(3):365-74. PubMed ID: 18428090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular complexity analysis of de novo designed ligands.
    Boda K; Johnson AP
    J Med Chem; 2006 Oct; 49(20):5869-79. PubMed ID: 17004702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
    Liu Q; Masek B; Smith K; Smith J
    J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer-based design of novel protein structures.
    Butterfoss GL; Kuhlman B
    Annu Rev Biophys Biomol Struct; 2006; 35():49-65. PubMed ID: 16689627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor flexibility in de novo ligand design and docking.
    Alberts IL; Todorov NP; Dean PM
    J Med Chem; 2005 Oct; 48(21):6585-96. PubMed ID: 16220975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site.
    Foloppe N; Chen IJ; Davis B; Hold A; Morley D; Howes R
    Bioorg Med Chem; 2004 Mar; 12(5):935-47. PubMed ID: 14980606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and selection of novel estrogen receptor ligands using the de novo structure-based design tool, SkelGen.
    Firth-Clark S; Willems HM; Williams A; Harris W
    J Chem Inf Model; 2006; 46(2):642-7. PubMed ID: 16562994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo drug design.
    Hartenfeller M; Schneider G
    Methods Mol Biol; 2011; 672():299-323. PubMed ID: 20838974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
    Moore JM
    Biopolymers; 1999; 51(3):221-43. PubMed ID: 10516573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in drug design methods: where will they lead?
    Dean PM
    Bioessays; 1994 Sep; 16(9):683-7. PubMed ID: 7980495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LEA3D: a computer-aided ligand design for structure-based drug design.
    Douguet D; Munier-Lehmann H; Labesse G; Pochet S
    J Med Chem; 2005 Apr; 48(7):2457-68. PubMed ID: 15801836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-based de novo design of drug-like molecules.
    Schneider G; Fechner U
    Nat Rev Drug Discov; 2005 Aug; 4(8):649-63. PubMed ID: 16056391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo design: balancing novelty and confined chemical space.
    Kutchukian PS; Shakhnovich EI
    Expert Opin Drug Discov; 2010 Aug; 5(8):789-812. PubMed ID: 22827800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo ligand design to an ensemble of protein structures.
    Todorov NP; Buenemann CL; Alberts IL
    Proteins; 2006 Jul; 64(1):43-59. PubMed ID: 16555306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical assessment of docking programs and scoring functions.
    Warren GL; Andrews CW; Capelli AM; Clarke B; LaLonde J; Lambert MH; Lindvall M; Nevins N; Semus SF; Senger S; Tedesco G; Wall ID; Woolven JM; Peishoff CE; Head MS
    J Med Chem; 2006 Oct; 49(20):5912-31. PubMed ID: 17004707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CONCERTS: dynamic connection of fragments as an approach to de novo ligand design.
    Pearlman DA; Murcko MA
    J Med Chem; 1996 Apr; 39(8):1651-63. PubMed ID: 8648605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
    Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.